Pharmacogenomics (PGx) drives better outcomes for your patients

The PGx profile of a patient offers valuable insights into the genetic variations that influence their medication metabolism and response, enabling healthcare providers to tailor medication selection and dosing adjustments based on individual genetic predispositions.

This personalized approach minimizes the risk for adverse medication reactions, reduces the likelihood of treatment failure, and may improve medication efficacy. Ultimately, integrating PGx data into clinical decision-making empowers providers to deliver more precise and effective care, leading to better health outcomes for patients. 

more than


medications have 
FDA recommendations based on PGx information

PGx by the Numbers

0 %
of people have gene variants
that change how their body
reacts to medicine1
0 %
have said they would be
comfortable getting a genetic test
to find one of these variants2
0 %

of patients would be more likely to 
take medication as prescribed if
PGx information was used to help 
select the drug or dose3

Pharmacogenomics provides the missing link:

The integration of pharmacology and genomics yields precise guidance tailored to individual genetic profiles, enhancing both the efficacy and safety of medication regimens for patients.

Pharmacogenomics has proven outcomes:

Medication prescriptions guided by PGx testing can
reduce clinically relevant adverse drug reactions by 30%.

Following pharmacogenomic interventions, studies prove reductions in hospitalizations and emergency department visits by 40% and 70%, respectively.

Utilizing genomic insights in medication and dosage choices may help:

Improve medication efficacy

Select the medications that are more likely to work effectively for each individual. 

Inform dosage

Genomic information can help determine how quickly an individual metabolizes a medication allowing for appropriate dose adjustments to increase effectiveness and reduce the risk for adverse effects. 

Reduce adverse effects

If an individual is likely to experience adverse effects from certain medications, an alternate medication can be considered.

DNAimpact for PGx Partners With Providers

From start to finish, our genetics experts will partner with you to keep you informed of patient participation and ensure that you have quick and easy access to understandable genomic insights from PGx testing. The result? Informed medication decisions that lead to improved patient outcomes and excellent patient care.

Notifications of patient enrollment & program completion

You will be notified as soon as your patient enrolls in DNAimpact for PGx. We anticipate a 2-4 week time frame between patient enrollment and receipt of test results. You will be notified once your patient has completed testing.

Provider Package: PGx Summary Report, Lab Results and Consult Notes

You will have access to all reports with easy-to-reference sections for interpretation, containing the most current supporting evidence (CPIC and FDA Labeling) to assist you in medication selection and dosing adjustments specific to your patient's genetic profile.

Peer-to-peer consults

We offer you one-on-one sessions with InformedDNA experts experienced in genetics and pharmacogenomics.

FAQs for Providers

A type of genetic test that is used to examine how a person’s genes can affect their response to medication.

A type of genetic test that is used to examine how a person’s genes can affect their response to medication.

A health plan-sponsored benefit program that offers to selected individuals access to digital education, PGx testing and personalized reports to empower patients and enable providers to optimize medication management and improve health outcomes. PGx summary reports are generated to provide information about gene-medication and medication-medication interactions that may impact how a patient metabolizes or responds to medications.

This program is offered by the patient’s insurance plan. The patient met specific criteria to be eligible to participate (for example, based on the medications they take).

As soon as your patient enrolls and provides your contact information, we will reach out via fax to let you know.

Yes, you will receive both the lab report and our user-friendly PGx Patient Results Summary. If the patient completed an appointment with our clinical experts, you will also receive a consult note from that appointment. The patient is encouraged to share all information with you. If you do not hear from your patient, we hope that you will initiate the communication to discuss their results and plan next steps.

Fulgent Genetics® is a full-service genomic testing company that performs the laboratory component of our PGx testing for the DNAimpact program. They’ll handle all of the details related to sending the test kit to the patient, receiving the sample, conducting the laboratory analysis, preparing and sending their technical lab report to both the patient, you and the DNAimpact ordering program.

Contact InformedDNA’s Customer Care at (888) 526-3601.

About InformedDNA

InformedDNA is a precision health company founded in 2007 as the first company to offer nationwide virtual Genetic Counseling. With one of the largest independent workforces of certified Genetic Counselors in the country, we cover all subspecialties and deliver fully-licensed Genetic Counseling and genetic test ordering in all 50 states. We strive to make genomics-informed care more accessible to people nationwide and to enable patients to take an active role in their healthcare decisions. We have managed genomic health benefits for more than 150 million covered lives and have navigated hundreds of thousands of people to the right genomics-based treatments or clinical trials.

Through innovative solutions that revolutionize the application of genomic insights, we enhance patient care, improve outcomes for all, and shape the future of precision health.

  1. Swen JJ, van der Wouden CH, Manson LE, et al; Ubiquitous Pharmacogenomics Consortium. A 12-gene pharmacogenetic panel to prevent adverse medication reactions: an open-label, multicentre, controlled, cluster-randomized crossover implementation study. Lancet. 2023;
  2. Clin Pharmacol Ther. 2012 Aug; 92(2): 235–242.
  3. Zhang L, Jacobson PA, Johnson ANK, et al. Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota. J Pers Med. 2022 Sep 30;12(10):1615. doi: 10.3390/jpm12101615.